The Medicare GLP-1 Bridge: A Clinical Eligibility Breakdown for Prescribers and Patients
The Medicare GLP-1 Bridge, launched July 1, 2026, has specific clinical eligibility criteria that both prescribers and patients should understand precisely — not just the headline $50 copay figure.
The clinical criteria that actually matter
- BMI documentation meeting the program's weight-management threshold
- Prescription for an FDA-approved brand-name medication specifically — compounded formulations don't qualify since Medicare requires an assigned NDC
- A participating Part D plan — not universal across all plans at launch
Sesame Care From $29
Prescribes FDA-approved brand-name medications compatible with Medicare Bridge eligibility.
Explore HealthRX’s compounded tirzepatide listing. Compounded medications are not FDA-approved; verify the current legal pathway, pharmacy and total price.
Explore HealthRX — tirzepatide ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.For patients navigating this with their provider
Confirm your specific Part D plan's Bridge participation status directly through Medicare.gov before assuming the $50 copay applies to your situation — plan-level variation is real, and a prescriber can't override that variation.